cancer research

New reporting highlights that people who survived cancer in childhood face a significantly elevated risk of serious mental health difficulties in adulthood, including depression, anxiety and other psychiatric conditions. The findings point to long-term psychological effects of early cancer diagnosis and treatment, and renew calls for survivors to receive sustained mental health monitoring and support, not just physical follow-up care, well into their adult lives.

A new study explains how the loss of genetic material on the Y chromosome may drive cancer development in men. Researchers say age-related loss of parts of the Y chromosome can impair tumour suppression, potentially explaining why certain cancers affect men more severely. The findings could point to new biomarkers and treatment approaches.

Researchers led by Dr. Jona Kayser at MPZPM report that physical processes in dense cell populations play a decisive role in determining the optimal timing of treatment cycles. The finding addresses treatment resistance, described as one of the key challenges in cancer and antibiotic therapy, and suggests treatment scheduling could be improved by accounting for how densely packed cells interact physically rather than relying on biological factors alone.

Researchers describe a 'proliferative pause' — a period when cancer cells spreading to the brain stop dividing before reactivating — and suggest this dormant phase could be a critical treatment window to stop brain metastases before they take hold. Targeting cells during this pause may prevent lethal secondary brain tumours in cancers prone to spreading there.

Mount Sinai has announced a collaborative research agreement to evaluate a novel liquid radioembolic agent for treating brain tumors. The therapy would deliver radiation directly to tumor tissue in liquid form, an approach being explored for cancers that are difficult to treat surgically. Details on the partner institution, trial design and timeline have not yet been released, and clinical results remain pending.

Researchers report that biological characteristics of prostate cancer tumours can help identify which patients are most likely to benefit from hormone therapy. The finding suggests tumour biology could be used to tailor treatment decisions rather than applying hormone therapy uniformly. Details of the study, including sample size and clinical impact, were not provided, but the work points toward more personalised prostate cancer care.

A Nature study reports that the p53 protein, best known as a tumour suppressor, prevents chromothripsis — the shattering of chromosomes — by keeping transcription and DNA replication in balance. When p53 is missing or inactive, these processes collide, causing catastrophic genome damage that can drive cancer development. The finding links a classic cancer gene to a new mechanism of genome protection, and researchers say it may refine how tumour evolution and genome instability are understood.